SEMA3F Antibody, FITC conjugated

1. SEMA3F plays a role as a tumor suppressor in Oral squamous cell carcinoma cell proliferation, migration and invasion. PMID: 29299034
2. in situ hybridization analysis revealed that Sema 3C and Sema 3F are expressed at the RNA level in the endometriosis affected peritoneum PMID: 27558236
3. Semaphorin 3F placenta tissue expression was significantly reduced in preeclampsia. In addition, semaphorin 3F level at delivery was significantly lower in serum, amniotic fluid and venous umbilical blood of preeclamptic patients compared with normal pregnant women. PMID: 28350837
4. There is a positive association between the expression of AKAP12 and Semaphorin 3F in prostate cancer, suggesting that the activation of Semaphorin 3F by AKAP12 may be involved in prostate cancer progression and metastasis. PMID: 28698137
5. Study demonstrates an anti-tumoral role of SEMA3F in ileal NETs. We thus suggest that SEMA3F and/or its cellular signaling pathway could represent a target for ileal NET therapy. PMID: 26447612
6. SEMA3F was downregulated in colorectal cancer tissues as compared to matched adjacent non-tumor tissues PMID: 26722466
7. A new SEMA3F transcript is expressed in all breast cell lines and breast cancer biopsies, and is translated into a new semaphorin 3F isoform. PMID: 26784191
8. SEMA3F-NRP2 interactions inhibit intracellular PI-3K activity, mTORC2-dependent signaling, RhoA activity and cytoskeletal stress fiber formation. PMID: 26156437
9. Data indicate that semaphorin 3F (SEMA3F) and its receptor neuropilin-2 (NRP2) are expressed in the thymus. PMID: 25068647
10. SEMA3F functions as a suppressor of colorectal cancer metastasis by down-regulating the ASCL2-CXCR4 signaling axis. PMID: 25866254
11. SEMA3F may represent an antilymphangiogenic metastasis suppressor gene widely lost during cancer progression, hence serving as a prognostic biomarker and an attractive target for therapeutic intervention to halt metastasis. PMID: 25952650
12. Infantile hemangioma-derived stem cells and endothelial cells are inhibited by SEMA3E and SEMA3F. PMID: 26086095
13. Data suggest that SEMA3F C-terminal domain exhibits high-affinity binding of neuropilin-1 (NRP1; thus inhibiting binding of vascular endothelial growth factor A to NRP1); this interaction may be involved in anti-angiogenic activity of SEMA3F. PMID: 24079887
14. A functional role for Semaphorin 3F in the outer retina where it acts as a vasorepulsive cue to maintain physiologic avascularity. PMID: 23603393
15. This study demonstrated a marked loss of noradrenergic and sensory nerve fibers in polyp mucosa, which was associated with a strong increase of semaphorin 3F and 3A. PMID: 22093159
16. It was concluded that hypoxia regulates VEGF and SE MA3F activities through transcriptional repression of their common receptor NRP2, providing a novel mechanism by which hypoxia induces tumor angiogenesis, growth and metastasis. PMID: 21610314
17. Endogenous SEMA3F acts as a suppressor of the growth and metastasis of human colorectal cancer cells. PMID: 21349996
18. SEMA3F, CLEC16A, LAMA3, and PCSK2 variants have roles in myocardial infarction in Japanese individuals PMID: 20036365
19. semaphorin-3B and semaphorin-3F have roles in ovarian cancer PMID: 20124444
20. Transient SEMA-3F gene transfection may inhibit the proliferation of Tca8113 cells. PMID: 18476556
21. Metastatic tumor cells overexpress c-myc, leading to upregulation of Id2 expression; the aberrantly elevated amount of Id2 represses SEMA3F expression and, as a consequence, enhances the ability of tumor cells to migrate and invade. PMID: 20388805
22. SEMA3F and VEGF have antagonistic actions affecting motility in primary tumor cell PMID: 12659673
23. SEMA3F is a potent metastasis inhibitor that targets both tumor and stromal cells PMID: 15520858
24. SEMA3F suppresses lung neoplasm progression in an experimental model PMID: 15967098
25. Results suggest that p53 negatively regulates tumor vessel formation and cell growth via the SEMA3F-NRP2 pathway. PMID: 17308083
26. combinations of sema3A and sema3F may be able to inhibit tumor angiogenesis more effectively than single semaphorins. PMID: 17569671
27. Semaphorin 3F mRNA forms a G quartet-containing structure, which is recognized with high affinity and specificity by the RGG box domain of the fragile X mental retardation protein. PMID: 17693432
28. ABL2/ARG is a novel mediator of SEMA3F-induced RhoA inactivation and collapsing activity. PMID: 18660502
29. SEMA3F loss was associated with changes in cell signaling: increased phospho-AKT in normoxia and hypoxia-induced factor 1alpha protein. Exogenous addition of SEMA3F could modulate ZEB-1-induced angiogenesis in a chorioallantoic membrane assay. PMID: 19177200
30. Semaphorin3F reverses Multicellular resistance by regulating alpha(v)beta3 PMID: 19657188
31. These data indicate that polymorphisms in SEMA3F are associated with prostate cancer risk and poor prognosis in Hispanic and nonHispanic white men PMID: 19683737
32. Soluble neuropilin-2Fc did not inhibit repulsion but increased the repellent effect of semaphorin 3F. PMID: 19790074
33. Sema3F inhibits tumor development from MDA-MB-435 and MDA-MB-231 and but not MCF-7 or MDA-MB-68 cancer cells. It inhibits tumor angiogenesis in all of the formed tumors. The inhibition is correlated with the expression of neuropilins of the tumors cells. PMID: 18818766

Show More

Hide All

HGNC: 10728

OMIM: 601124

KEGG: hsa:6405

STRING: 9606.ENSP00000002829

UniGene: Hs.32981